Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B, Groen HJM, Ligtenberg MJL, Grünberg K, Monkhorst K, de Langen AJ, Boelens MC, Paats MS, von der Thüsen JH, Dinjens WNM, Solleveld N, van Wezel T, Gelderblom H, Hendriks LE, Speel EM, Theunissen TE, Kroeze LI, Mehra N, Piet B, van der Wekken AJ, Ter Elst A, Timens W, Willems SM, Meijers RWJ, de Leng WWJ, van Lindert ASR, Radonic T, Hashemi SMS, Heideman DAM, Schuuring E, van Kempen LC. Koopman B, et al. Among authors: van der wekken aj, van lindert asr, van kempen lc, van wezel t. Oncologist. 2021 Aug;26(8):e1347-e1358. doi: 10.1002/onco.13580. Epub 2020 Nov 10. Oncologist. 2021. PMID: 33111480 Free PMC article.
KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.
Niemantsverdriet M, Schuuring E, Elst AT, van der Wekken AJ, van Kempen LC, van den Berg A, Groen HJM. Niemantsverdriet M, et al. Among authors: van der wekken aj, van kempen lc, van den berg a. J Thorac Oncol. 2018 Dec;13(12):e249-e251. doi: 10.1016/j.jtho.2018.07.103. J Thorac Oncol. 2018. PMID: 30467046 Free article. No abstract available.
Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics.
Eijkelenboom A, Tops BBJ, van den Berg A, van den Brule AJC, Dinjens WNM, Dubbink HJ, Ter Elst A, Geurts-Giele WRR, Groenen PJTA, Groenendijk FH, Heideman DAM, Huibers MMH, Huijsmans CJJ, Jeuken JWM, van Kempen LC, Korpershoek E, Kroeze LI, de Leng WWJ, van Noesel CJM, Speel EM, Vogel MJ, van Wezel T, Nederlof PM, Schuuring E, Ligtenberg MJL. Eijkelenboom A, et al. Among authors: van kempen lc, van wezel t, van noesel cjm, van den berg a, van den brule ajc. Virchows Arch. 2019 Jun;474(6):673-680. doi: 10.1007/s00428-019-02555-3. Epub 2019 Mar 19. Virchows Arch. 2019. PMID: 30888490 Free PMC article.
Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
Steeghs EMP, Kroeze LI, Tops BBJ, van Kempen LC, Ter Elst A, Kastner-van Raaij AWM, Hendriks-Cornelissen SJB, Hermsen MJW, Jansen EAM, Nederlof PM, Schuuring E, Ligtenberg MJL, Eijkelenboom A. Steeghs EMP, et al. Among authors: van kempen lc. BMC Cancer. 2020 Apr 7;20(1):291. doi: 10.1186/s12885-020-06785-6. BMC Cancer. 2020. PMID: 32264863 Free PMC article.
Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P, Koopman B, Kok K, Ter Elst A, Schuuring E, van Kempen LC, Timens W, Hiltermann TJN, Groen HJM, van den Berg A, van der Wekken AJ. Meng P, et al. Among authors: van der wekken aj, van kempen lc, van den berg a. Lung Cancer. 2020 Aug;146:358-361. doi: 10.1016/j.lungcan.2020.05.036. Epub 2020 Jun 4. Lung Cancer. 2020. PMID: 32534795 Free article.
Non-small-cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy.
Koopman B, Hiddinga BI, Platteel I, Kluiver JL, Timens W, Mulder AB, van Doesum JA, Schuuring E, Diepstra A, van Kempen LC. Koopman B, et al. Among authors: van doesum ja, van kempen lc. Histopathology. 2021 Jun;78(7):1043-1046. doi: 10.1111/his.14326. Epub 2021 Apr 3. Histopathology. 2021. PMID: 33410163 Free PMC article. No abstract available.
Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing.
Allahyar A, Pieterse M, Swennenhuis J, Los-de Vries GT, Yilmaz M, Leguit R, Meijers RWJ, van der Geize R, Vermaat J, Cleven A, van Wezel T, Diepstra A, van Kempen LC, Hijmering NJ, Stathi P, Sharma M, Melquiond ASJ, de Vree PJP, Verstegen MJAM, Krijger PHL, Hajo K, Simonis M, Rakszewska A, van Min M, de Jong D, Ylstra B, Feitsma H, Splinter E, de Laat W. Allahyar A, et al. Among authors: van der geize r, van kempen lc, van min m, van wezel t. Nat Commun. 2021 Jun 7;12(1):3361. doi: 10.1038/s41467-021-23695-8. Nat Commun. 2021. PMID: 34099699 Free PMC article.
A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses.
Koopman B, Cajiao Garcia BN, Kuijpers CCHJ, Damhuis RAM, van der Wekken AJ, Groen HJM, Schuuring E, Willems SM, van Kempen LC. Koopman B, et al. Among authors: van der wekken aj, van kempen lc. Cancers (Basel). 2021 Jul 20;13(14):3641. doi: 10.3390/cancers13143641. Cancers (Basel). 2021. PMID: 34298851 Free PMC article.
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.
Koopman B, Groen HJM, Schuuring E, Hiltermann TJN, Timens W, den Dunnen WFA, van den Berg A, Ter Elst A, van Kruchten M, Kluiver JL, Hiddinga BI, Hijmering-Kappelle LBM, Groves MR, Vilacha JF, van Kempen LC, van der Wekken AJ. Koopman B, et al. Among authors: van kruchten m, van der wekken aj, van kempen lc, van den berg a. Clin Lung Cancer. 2022 Mar;23(2):e104-e115. doi: 10.1016/j.cllc.2021.06.011. Epub 2021 Jul 3. Clin Lung Cancer. 2022. PMID: 34325996 Free article. Review.
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
van der Leest P, Hiddinga B, Miedema A, Aguirre Azpurua ML, Rifaela N, Ter Elst A, Timens W, Groen HJM, van Kempen LC, Hiltermann TJN, Schuuring E. van der Leest P, et al. Among authors: van kempen lc. Mol Oncol. 2021 Nov;15(11):2910-2922. doi: 10.1002/1878-0261.13090. Epub 2021 Sep 25. Mol Oncol. 2021. PMID: 34449963 Free PMC article.
115 results